JP Morgan Chase’s Freeline Therapeutics Holdings plc American Depositary Shares FRLN Stock Holding History

JP Morgan Chase’s Portfolio FRLN Stock Details FRLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-67,053	Closed	-$426K	–	8066
2023 Q4	$426K	Buy	+67,053	New	+$359K	﹤0.01%	4899
2022 Q2	–	Sell	-44	Closed	-$1K	–	7023
2022 Q1	$1K	Buy	+44	New	+$816	﹤0.01%	6511

JP Morgan Chase's FRLN Position: Q1 2024 in Review

JP Morgan Chase sold out of Freeline Therapeutics Holdings plc American Depositary Shares (FRLN) in Q1 2024, closing a stake of 67,053 shares — an estimated $426K sold.

JP Morgan Chase first reported a position in FRLN in Q1 2022 and held it in 2 quarters. The position peaked at $426K in Q4 2023. 0 funds tracked by Wall St. Rank hold FRLN as of Q1 2024.

JP Morgan Chase reported no remaining Freeline Therapeutics Holdings plc American Depositary Shares position as of Q1 2024 after selling out during the quarter.
JP Morgan Chase sold 67,053 Freeline Therapeutics Holdings plc American Depositary Shares shares in Q1 2024, an estimated $426K.
JP Morgan Chase first reported a position in Freeline Therapeutics Holdings plc American Depositary Shares in Q1 2022 and held it in 2 quarters.
JP Morgan Chase's Freeline Therapeutics Holdings plc American Depositary Shares position peaked at $426K in Q4 2023.
0 funds tracked by Wall St. Rank held Freeline Therapeutics Holdings plc American Depositary Shares as of Q1 2024.

Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.